Psoriatic arthritis

psoriatic.PIP_.JPG

Biologic Persistence in Psoriatic Arthritis and Psoriasis
Save

May 19, 2022

Two recent studies examined the durability and persistence of biologic agents in patients with psoriasis (PSO) and psoriatic arthritis (PsA) and while some differences were noted overall persistence was low 3 years later.

RNL 2022: Spondyloarthritis Spectrum
Save

May 18, 2022

This RheumNow Live 2022 session features highlights from lectures on Spondyloarthritis.

- Microbiome in Spondyloathritis - Jose Scher, MD

- Axial Psoriatic Arthritis - Philip Mease, MD

- Juvenile Spondyloathritis - Pamela Weiss, MD

Bimekizumab Development Delayed by FDA
Save

May 16, 2022

UCB announced they have received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis (PSO).

Can You Reduce Frequency of Methotrexate Monitoring?
Save

May 12, 2022

Observational research presented at the British Society for Rheumatology meeting suggest that, based on the COVID-19 pandemic experience, reduced frequency of routine lab monitoring in patients receiving weekly methotrexate therapy for rheumatoid arthritis (RA) was not associated with an

We had a great TNR this week. Playback now available in case you missed it. This webinar presented excerpts from these lectures along with Q & A Psoriatic Arthritis Guidelines Drug Targeting in PsA PsA Registries and Real World Data https://t.co/al17KLQm0j https://t.co/O4SvMU37Lg

Links:

https://bit.ly/3yxDWEY

Dr. John Cush @RheumNow( View Tweet )

May 12, 2022

Making You the Expert of You! (Smart Rules for Patients) You’ve scheduled an appointment with your medical provider - how do you make the most of it?https://t.co/62mTqk4ksL https://t.co/gr7Hvt7EI3

Links:

https://bit.ly/3L7VcTD

Dr. John Cush @RheumNow( View Tweet )

May 12, 2022

psoriasis,arm,hand,rash,elbow

Bimekizumab's Favorable Safety Profile in Psoriasis
Save

May 11, 2022

A 2-year safety study of bimekizumab, the dual IL-17A/F inhibitor, plaque psoriasis patients showed bimekizumab (BMK), to be effective, well tolerated, with no new safety concerns other than a modest risk of oral candidiasis.

RNL 2022: Psoriatic Arthritis Advances
Save

May 11, 2022

Tuesday Nite Rheumatology on 10 May 2022 featured session highlights from RheumNow Live 2022.

This webinar presented exerpts from these lectures along with audience Q & A

Psoriatic Arthritis Guidelines Arthur Kavanaugh, MD

Drug Targeting in PsA Bruce Kirkham

Interested in what we covered in the month of April? You can find all our PsA content at the link below. What was your biggest takeaway from our PsA All the Way campaign?https://t.co/hl0HKggULj https://t.co/O1QMibJ4qA

Links:

https://bit.ly/3kQPDyo

Dr. John Cush @RheumNow( View Tweet )

May 11, 2022

Patient,instruction

Making You the Expert of You! (Smart Rules for Patients)
Save

May 10, 2022

You’ve scheduled an appointment with your medical provider - how do you make the most of it? We've gathered these tips and suggestions to share with patients.

TOMORROW! Register for our 5/10 Tuesday Night Rheumatology on PsA Advances. This webinar will feature highlights from: PsA Guidelines Arthur Kavanaugh, MD Drug Targeting in PsA Bruce Kirkham, MD PsA Registries and Real World Data Alexis Ogdie, MDhttps://t.co/0fNuHz6wVy https://t.co/KssNJ41Wqz

Links:

https://bit.ly/3P8fbEZ

Dr. John Cush @RheumNow( View Tweet )

May 09, 2022

Hyperuricemia as a biomarker of severe #PsA? Study of 242 PsA pts 30% had hyperuricemia & 6% had gout. Hyperuricemia was significantly associated with age, comorbidity, perph polyarthritis, Jt destruction, less response to treatment. https://t.co/U5wAQdWLdC https://t.co/QfoaogDeun

Links:

https://bit.ly/3kPieEk

Dr. John Cush @RheumNow( View Tweet )

May 08, 2022

Large Korean population study compares pts w/ palmoplantar psoriasis vs psoriasis and PPP pts have more risk for ankylosing spondylitis (aOR 1.37) & Graves dz (aOR 1.4) but lower risk for PsA (aOR 0.54), SLE (0.67); Sjögren (0.70); vitiligo (0.53) https://t.co/0fv2vnFBPf https://t.co/PJMagIeZ2F

Links:

https://bit.ly/3vSBDuv

Dr. John Cush @RheumNow( View Tweet )

May 07, 2022

Study of 17 homeless RA or PsA pts - less clinic access (80% vs 91%), more ED use (20 vs 5), less DMARDs (43% vs 100%), more steroids (29% vs 0%); 83% unable to work due to health. Greatest need - dental , PT, knee surgery, employment & housing https://t.co/VHnTR0MTkr https://t.co/JDZTELz2qB

Links:

https://bit.ly/3ORVHED

Dr. John Cush @RheumNow( View Tweet )

May 06, 2022

There is 1.4 million transgender persons in the US. ACP has published a guideline "Care of the Transgender Patient" addressing health disparities, certain cancers, substance abuse, mental health conditions, infections, and chronic diseases. https://t.co/AoBeOzv9YH https://t.co/jKabVELPxH

Links:

https://bit.ly/3P3Fsoa

Dr. John Cush @RheumNow( View Tweet )

May 06, 2022

Study of 13 European registries on durability/effect of interleukin-17 (IL-17) inhibition with secukinumab: among 2,017 PsA on secukinumab, retention rates were 86% and 76% at 6 and 12 mos, with 12 mo remission rate of 11% to 16% https://t.co/03sJBSbUy6

Links:

https://bit.ly/3w4Az5o

Dr. John Cush @RheumNow( View Tweet )

May 04, 2022

Neural networks of high-res quantitative CT (HR-pQCT) scans allowed for 3D imaging of MCP2 to differentiate normals from #RA & #PsA. 932 of 617 ppts correct AuROC for HC 82%, RA 75%, PsA 68%. UA pts read as 86% RA,11% PsA, & 3% HC https://t.co/wSQgllYgug https://t.co/yA6g55SpeC

Links:

https://bit.ly/3Fj2Oli

Dr. John Cush @RheumNow( View Tweet )

May 04, 2022

Thanks so much to all who contributed to April's PsA All the Way campaign on RheumNow. You can find all our PsA content at the link below. Did you learn anything new about PsA from our coverage?https://t.co/Mo7Yf2cu4i https://t.co/LvpuLtF4Mv

Links:

https://bit.ly/3sbdayc

Dr. John Cush @RheumNow( View Tweet )

May 04, 2022

Rheumatologic diagnosis through hand exam by Dr. Sarah Chung @ACPinternists #rheumatology #rheumtwitter #MedEd #rheumatoidarthritis #BJHM #Hospitalmedicine #IM2022 #MedTwitter 👇🏽 https://t.co/qR4zNa4NcX

Brown Journal of Hospital Medicine @BrownJHM( View Tweet )

May 03, 2022

Hyperuricemia as a biomarker of severe #PsA? Study of 242 PsA pts 30% had hyperuricemia & 6% had gout. Hyperuricemia was significantly associated with age, comorbidity, perph polyarthritis, Jt destruction, less response to treatment. https://t.co/NiPTbknD57 https://t.co/HOC2Bev4R6

Links:

https://bit.ly/3vXqPd9

Dr. John Cush @RheumNow( View Tweet )

May 02, 2022

We completed a whole month of super-charged, focused coverage & education on #PsA.THANKS to the many mavens who contributed! In PSA - "Unless someone like you cares a whole awful lot, nothing is going to get better. It’s not." -Dr. Seuss, The Lorax https://t.co/Y58klwbS4V https://t.co/f2pnuypwyr

Links:

https://bit.ly/38LGYus

Dr. John Cush @RheumNow( View Tweet )

May 02, 2022

Playback now available! Watch our Tuesday Nite Rheumatology, held April 26th, 2022, which featured a Journal Club panel discussion about two important studies.https://t.co/RjFRFt6oJQ https://t.co/zOxCDC1atS

Links:

https://bit.ly/3F4hyUF

Dr. John Cush @RheumNow( View Tweet )

May 01, 2022

RheumNow Podcast square

$30 Billion and Counting (4.29.2022)
Save

Apr 29, 2022

Dr. Jack Cush reviews the news and journal reports and takes viewer questions this week.

Perplexing Oligoarthritis, +FHx, But no psoriasis QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022https://t.co/ljZ1cStNTy https://t.co/8RMFFWjDEP

Links:

https://bit.ly/3xVKXz6

Dr. John Cush @RheumNow( View Tweet )

Apr 27, 2022

PsA Journal Club - Fecal Transplant & H2H IXE vs ADA
Save

Apr 27, 2022

Playback now available! Watch our Tuesday Nite Rheumatology, held April 26th, 2022, which featured a Journal Club panel discussion about two important studies.

×